TITLE

Commentary

PUB. DATE
January 2013
SOURCE
Gastroenterology & Hepatology;Jan2013 Supplement, p18
SOURCE TYPE
Academic Journal
DOC. TYPE
Opinion
ABSTRACT
The author discusses some of the studies presented at the 2012 American Association for the Study of Lung Diseases (AASLD) meeting which focuses on the management of hepatitis C virus (HCV) infection. He mentions the Anemia Management Study which examines the impact of timing and magnitude of ribavirin dose reduction to sustained virologic response (SVR) of HCV patients. He states that sustainable new information for the treatment and understanding of hepatitis C therapy comes every six months.
ACCESSION #
86416043

 

Related Articles

  • A 12-Week Interferon-Free Treatment Regimen with ABT-450/r, ABT-267, ABT-333, and Ribavirin Achieves High SVR12 Rates.  // Gastroenterology & Hepatology;Jan2013 Supplement, p11 

    The article presents a study on the administration of ritonavir-boosted human immune virus (HIV) protease inhibitors among healthy volunteers. It states that the study has three clinical trials including the phase II hepatitis C virus (HCV)/(HIV) co infection study, the phase III sprint-2 study,...

  • An Interferon-Free, Ribavirin-Free 12-Week Regimen of Daclatasvir, Asunaprevir, and BMS-791325 Achieved High SVR4 Rates.  // Gastroenterology & Hepatology;Jan2013 Supplement, p17 

    The article presents a study which examines the peginterferon-free, ribavirin-free regimen of declatasvir, asunaprevir, and BMS-791325. The 32 genotype 1 hepatitis C virus (HCV) infected patients were given asunaprevir, declatasvir, and BMS-791325 for 24 weeks in group one and 12 weeks in group...

  • High Rate of SVR with the All-Oral Combination of Daclatasvir Plus Sofosbuvir with or without Ribavirin.  // Gastroenterology & Hepatology;Jan2013 Supplement, p16 

    The article presents a study on the introduction of oral agents which can effectively cure hepatitis C virus (HCV) infection. It says that direct-acting antiviral agents that can be taken orally includes the NS5A replication complex inhibitor declatasvir and the nucleotide analogue NS5B...

  • News From the Liver Meeting. Lichtenstein, Gary R. // Gastroenterology & Hepatology;Dec2014, Vol. 10 Issue 12, p763 

    An introduction is presented in which the editor discusses the 2014 Liver Meeting held in Boston, Massachusetts on November 7-11 and articles within the issue including an interview with Dr. Nezam H. Afdhal on the ION trials, hepatitis B virus-HIV coinfection and the evaluation of data for the...

  • THE NEXT WAVE OF HCV CARE: ALL-ORAL TREATMENT STRATEGIES. Sulkowski, Mark // Johns Hopkins Advanced Studies in Medicine;Jun2014, Vol. 14 Issue 1, p16 

    Recently approved direct-acting antiviral agents (DAAs) are recommended for use in combination with peginterferon (PEG) for interferon (IFN)-eligible patients. PEG is associated with significant adverse events, and many patients are not eligible for PEG therapy due to comorbid conditions or...

  • ANONYMOUS STUDY OF HEPATITIS C VIRUS (HCV) PREVALENCE IN LIVER TRANSPLANT SURGEONS.  // Gut;Apr2004 Supplement 3, Vol. 53, pA81 

    The risk of hepatitis C virus (HCV) transmission from patients to surgeons is related to the prevalence of HCV in the surgical patient population. As HCV related cirrhosis is the commonest indication for liver transplantation in Europe and North America, liver transplant surgeons would be...

  • The relationship between anemia, liver disease, and hepcidin levels in hemodialysis patients with hepatitis. Zumrutdal, A.; Sezgin, N. // Indian Journal of Nephrology;Nov/Dec2012, Vol. 22 Issue 6, p415 

    We investigated the role of hepcidin in ameliorating anemia in hemodialysis patients with hepatitis. A total of 72 hemodialysis patients with hepatitis were classified according to their requirement of erythropoietin (EPO). Anemia parameters, C-reactive protein (CRP), and biochemical...

  • The 25th Annual Congress of the Hungarian Society of Nephrology, Szeged, 25–27 September 2008. Túri, Sándor // Nephrology Dialysis Transplantation;Apr2009, Vol. 2 Issue 2, p195 

    Information about several topics discussed at the "25th Annual Congress of the Hungarian Society of Nephrology" held in Szeged, Hungary from September 25 to 27, 2008 is presented. Topics include the potential use of biosimilars, the impact of erythropoietin treatment transitory withholding in...

  • ABSTRACT SUMMARY.  // Gastroenterology & Hepatology;Jan2013 Supplement, p10 

    The article presents abstracts on medical topics which include a clinical decision tool to predict sustained virologic response (SVR) and treatment response in patients treated with ribavirin and boceprever plus peginterferon, a comparison of twice-daily administration of telaprevir versus every...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics